Last reviewed · How we verify
GS1191-0445 injection
GS1191-0445 injection is a therapeutic agent that targets a specific molecular pathway.
GS1191-0445 injection is a therapeutic agent that targets a specific molecular pathway. Used for Treatment of a specific type of cancer.
At a glance
| Generic name | GS1191-0445 injection |
|---|---|
| Sponsor | Gritgen Therapeutics Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
While the exact mechanism of GS1191-0445 injection is not well-documented, it is believed to modulate the activity of a particular protein or receptor, leading to its therapeutic effects.
Approved indications
- Treatment of a specific type of cancer
Common side effects
- Injection site reactions
- Fatigue
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GS1191-0445 injection CI brief — competitive landscape report
- GS1191-0445 injection updates RSS · CI watch RSS
- Gritgen Therapeutics Co., Ltd. portfolio CI